

Curriculum Vitae

| | | |
|--|---|----------------|
| Name: Professor Dr.Punnee Pitisuttithum ศาสตราจารย์แพทย์หญิง พรรณี ปิติสุทธิธรรม | Position: Head, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University | |
| Office Address: | | |
| Faculty of Tropical Medicine, Mahidol University 420/6 Ratchawithi Rd, Ratchathewi, Bangkok 10400, Thailand | Tel: (662) 643 5599 Fax: (662) 643 5598 Email: punnee.pit@mahidol.ac.th | |
| Education Background: | | |
| Institution and Location | Degree | Year(s) |
| Thai Medical Council, Bangkok, Thailand | Diploma Thai Board of Internal Medicine | 1993 |
| Faculty of Medicine, Ramathibodee, Mahidol University, Bangkok, Thailand | D.C.M. | 1992 |
| Bangkok School of Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand | D.T.M.&H. | 1984 |
| Lady Hardinges Medical College, Delhi University, N-Delhi, India | M.B., B.S. | 1982 |
| Premedical Science, Mahidol University, Bangkok, Thailand | | 1978 |
| Administrative Appointments: Oct 2006 - present: Head, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine 2002 – present: Member, Faculty Senate, Mahidol University, Bangkok 2002 – present: Director, Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok 2000 – present: Chief of Clinical Infectious Diseases Research Unit, Department of Clinical Tropical Medicine, Mahidol University, Bangkok | | |
| Academic Appointments: Aug 2004 – present: Professor, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok Jul 2009 – present: Member, Research Support and Vaccine Development Subcommittee, National Vaccine Committee, Ministry of Public Health, Thailand Dec 2011 – present: Member, WHO-UNAIDS HIV Vaccine Advisory Committee (VAC) May 2011 – present: IAVI Clinical Trial Subcommittee, IAVI International AIDS Vaccine Initiative Dec 2011 – present: คณะทำงานจัดทำร่างแผนแม่บทการพัฒนาบุคลากรด้านวัคซีนของประเทศไทย สถาบันวัคซีนแห่งชาติ Apr 2012 – present: คณะกรรมการจัดทำพจนานุกรมศัพท์เภสัชศาสตร์ ราชบัณฑิตยสถาน | | |
| Award: The highest citation count for research papers in 2005-2009, based on the SCOPUS database from Mahidol University Awards for Research Papers Published in International Journals (2010). | | |
| Areas of Specialization/Expertise: <ul style="list-style-type: none"> ▪ Tropical Medicine ▪ Clinical studies (Phase I, II, III Drug Trials) of Tropical Diseases eg. Cryptococcal meningitis in AIDS; oral candidiasis, Chinese herbal medicine for AIDS. ▪ Vaccine Trials(Phase I, II, III) of HIV/AIDS vaccine, Human Papilloma Virus vaccine against cervical cancer, Cholera oral vaccine, Shigella vaccine, Rota virus vaccine, Varicella vaccine, Measle vaccine etc. | | |
| Experience Projects (the past 5 years): Tremendous experiences in conducting vaccine trials extending from phase I, II to efficacy phase III trials of vaccine against various infectious diseases e.g. | | |

| | |
|--------------|--|
| 2013-ongoing | Comparative Randomized, Single Dose, Two-Way Crossover, Open-Label, Pilot Study to Determine the Bioequivalence of Azithromycin Formulations, Azycin® for Oral Suspension 200 mg/5 mL and Zithromax® for Oral Suspension 200 mg/5 mL, after Oral Administration to Healthy Thai Male Volunteers under Fasting Conditions |
| 2013-ongoing | Comparative Randomized, Single Dose, Two-Way Crossover, Open-Label Pilot Study to determine the Bioequivalence of Pantoprazole Formulations, Pantoprazole GPO 40 mg Tablets and Controloc® 40 mg Tablets, After Oral Administration to Healthy Thai Volunteers Under Fed Conditions |
| 2013-ongoing | Comparative Randomized, Single Dose, Two-Way Crossover, Open-Label Study to Determine the Bioequivalence of Lopinavir/Ritonavir Formulations, Lopinavir/Ritonavir GPO 100/25 mg Tablets and Aluvia® 100/25 mg Tablets, after Oral Administration to Healthy Thai Male Volunteers under Fasting Conditions |
| 2013-ongoing | Acceptability of an influenza vaccine among the elderly in Bangkok and surrounding provinces, Thailand |
| 2013-ongoing | Community Engagement Program to Assess and Prepare Muang District Community in Nakhon Phanom Province for Participation in a Phase III Government Pharmaceutical Organization (GPO) Seasonal Trivalent Live Attenuated Influenza Vaccine Trial |
| 2012 | Capability Assessment for Supporting Research and Development of Vaccine in Thailand |
| 2012-ongoing | Randomized, Double Blind Evaluation of Different One-Year Boosts after Sanofi Pasteur Live Recombinant ALVAC-HIV (vCP1521) and Global Solutions for Infectious Diseases (GSID) gp120 B/E (AIDSVAX® B/E) Prime-Boost Regimen in HIV-uninfected Thai Adults |
| 2012-ongoing | Phase I safety and immunogenicity of live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 (H5N2) in healthy Thais volunteers |
| 2011-ongoing | Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Participants in the HIV Vaccine Efficacy Trial RV144: "Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming with VaxGen gp120 B/E (AIDSVAX® B/E) Boosting in HIV-uninfected Thai Adults |
| 2011-ongoing | Efficacy and safety of a novel Tetravalent Dengue vaccine in healthy children aged 2 to 14 years in Asia |
| 2010-2011 | Prospective surveillance of febrile illness for dengue-endemic areas in Asia |
| 2009-2011 | Phase I/II safety and immunogenicity of pandemic live attenuated influenza vaccine (PLAIV) candidate strain A/17/CA/2009/38 (H1N1) in healthy Thais |
| 2009-ongoing | A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 year olds) with a Comparison to Young Women (16 to 26 year olds) |
| 2008-2009 | Measurement of Anogenital Wart Burden and Cost of Illnesses in Thailand |
| 2008-2009 | A Phase 2b/3, randomized, double blind, dose confirming study of the safety, |

| | |
|-----------|---|
| | efficacy and tolerability of apricitabine versus lamivudine in treatment-experienced HIV-1 infected patients with the M184V mutation in reverse transcriptase. |
| 2007-2009 | Measuring Herpes Zoster and Post-Herpetic Neuralgia Associated Burden of Illness and Health Care Utilcation and Costs in Thailand |
| 2007-2008 | Assessing the psychosocial burden in women with an abnormal pap results after screening interventions. |
| 2006-2009 | Establishment of a <i>Shigella sonnei</i> Challenge Model for Evaluation of Future Vaccine Candidates |
| 2005-2010 | A study to evaluate the efficacy of GARDASIL™ (Human Papillomavirus [types 6,11,16,18] recombinanat vaccine) in reducing the incidence of HPV 6-,11-,16-, and 18- related CIN, AIS, and cervical cancer, and HPV 6-,11-,16-, and 18-related external genital warts, VIN, ValN, vulvar cancer, and vaginal cancer in 26- to- 45 year-old women |
| 2002-2008 | A World-wide Phase I, Dose-escalating Study of the Safety, Tolerability and Immunogenicity of a 3-Dose Regimen of the MRKAd 5 HIV-1 gag Vaccine in healthy adults. |

PUBLICATIONS (the past 3 years):

Capeding MR, Chua MN, Hadinegoro SR, Hussain I, Nallusamy R, Pitisuttithum P, Rusmil K, Thisyakorn U, Thomas SJ, Tran NH, Wirawan DN, Yoon IK, Bouckennooghe A, Hutagalung Y, Laot T, Wartel TA. Dengue and Other Common Causes of Acute Febrile Illness in Asia: An Active Surveillance Study in Children. PLoS Negl Trop Dis. 2013 Jul 13;7(7):e2331.

Pitisuttithum P, Excler JL, Kim J. Beyond RV144 Efficacy Results: An Update. Procedia in Vaccinology. Available online at www.sciencedirect.com. 7(2013) 49-56.

Liu P, Yates NL, Shen X, Bonsignori M, Moody MA, Liao HX, Fong Y, Alam SM, Overman RG, Denny T, Ferrari G, Ochsenbauer C, Kappes JC, Polonis VR, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Montefiori DC, Gilbert P, Michael NL, Kim JH, Haynes BF, Tomaras GD. Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees. J Virol. 2013 Jul;87(14):7828-36.

Duangrithi D, Thanachartwet V, Desakorn V, Jittruckhai P, Phojanamongkolkij K, Rienthong S, Chuchottaworn C, Pitisuttithum P. Impact of diabetes mellitus on clinical parameters and treatment outcomes of newly diagnosed pulmonary tuberculosis patients in Thailand. Int J Clin Pract. 2013 Jun 10. [Epub ahead of print]

Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, Poling B, Nicholson CO, Zhang R, Lu X, Parks R, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Gilbert PB, Kim JH, Michael NL, Montefiori DC, Haynes BF. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A. 2013 May 28;110(22):9019-24.

Kyaw NL, Thanachartwet V, Kiertiburanakul S, Desakorn V, Chamnanchanunt S, Chierakul W, Manosuthi W, Pitisuttithum P, Sungkanuparph S. Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand. Southeast Asian J Trop Med Public Health. 2013 Mar;44(2):232-43.

Phonrat B, Pitisuttithum P, Chamnanchanunt S, Puthavathana P, Ngaosuwankul N, Louisirothanakul S, Dhitavat J, Thirapakpoomanunt S, Chokevivat V, Wibulpolprasert W. Safety and Immune Responses Following Administration of H1N1 Live Attenuated Influenza Vaccine in Thais. Vaccine. 2013 Mar 1;31(11):1503-9.

Kaewkungwal J, Pitisuttithum P, Rerks-Ngarm S, Nitayaphan S, Khamboonruang C, Kunasol P, Suntharasamai P, Pungpak S, Vanijanonta S, Bussaratid V, Maek-A-Nantawat W, Dhitavat J, Thongcharoen P, Pawarana R,

Sabmee Y, Benenson M, Morgan P, O'Connell R, Kim JH. Issues in Women's Participation in a Phase III Community HIV Vaccine Trial in Thailand. *AIDS Res Hum Retroviruses*. 2013 Jan 23. [Epub ahead of print]

Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, Liu P, Lu X, Parks RJ, Montefiori DC, Ferrari G, Pollara J, Rao M, Peachman KK, Santra S, Letvin NL, Karasavvas N, Yang ZY, Dai K, Pancera M, Gorman J, Wiehe K, Nicely NI, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Sinangil F, Kim JH, Michael NL, Kepler TB, Kwong PD, Mascola JR, Nabel GJ, Pinter A, Zolla-Pazner S, Haynes BF. Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. *Immunity*. 2013 Jan 24;38(1):176-86. doi: 10.1016/j.immuni.2012.11.011.

Alam SM, Liao HX, Tomaras GD, Bonsignori M, Tsao CY, Hwang KK, Chen H, Lloyd KE, Bowman C, Sutherland L, Jeffries TL Jr, Kozink DM, Stewart S, Anasti K, Jaeger FH, Parks R, Yates NL, Overman RG, Sinangil F, Berman PW, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Karasavva N, Rerks-Ngarm S, Kim JH, Michael NL, Zolla-Pazner S, Santra S, Letvin NL, Harrison SC, Haynes BF. Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion. *J Virol*. 2013 Feb; 87(3):1554-68.

Luvira V, Chamnanchanunt S, Bussaratid V, Leaungwutiwong P, Pitisuttithum P. Seroprevalence of Latent Cytomegalovirus Infection among Elderly Thais. *Southeast Asian J Trop Med Public Health*. 2012 Nov; 43(6):1419-25.

Bodhidatta L, Pitisuttithum P, Chamnanchanant S, Chang KT, Islam D, Bussaratid V, Venkatesan MM, Hale TL, Mason CJ. Establishment of a *Shigella sonnei* human challenge model in Thailand. *Vaccine*. 2012 Nov 19;30(49):7040-5.

Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, Tomaras GD, Currier JR, Jiang M, Magaret C, Andrews C, Gottardo R, Gilbert P, Cardozo TJ, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Paris R, Greene K, Gao H, Gurunathan S, Tartaglia J, Sinangil F, Korber BT, Montefiori DC, Mascola JR, Robb ML, Haynes BF, Ngauy V, Michael NL, Kim JH, de Souza For The Moph Taveg Collaboration MS. The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. *AIDS Res Hum Retroviruses*. 2012 Oct 4.

Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, DeVico A, Evans DT, Ferrari G, Liao HX, Haynes BF. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. *J Virol*. 2012 Nov;86(21):11521-32.

Liao L, Bonsignori M, Hwang K, Moody AM, Park R, Crawford S, Chen H, Jeffries TL, Cooper M, Lu X, De R, Karasavvas N, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, Tovanabutra S, Pitisuttithum P, Tartaglia J, Sinangil F, Kim J, Michael NL, Tomaras GD, Yang Z, Dai K, Pancera M, Nabel GJ, Mascola JR, Kwong PD, Pinter A, Zolla-Pazner S, Alam MS, Haynes BF. Design of an HIV Env Antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2 (Abstract). *AIDS VACCINE 2012, Boston, USA, Sep 9-12, 2012* p.69.

Pollara J, Bonsignori M, Moody M, Alam M, Liao H, Hwang K, Pickeral J, Kappes J, Ochsenbauer c, Soderberg K, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Montefiori D, Robinson JE, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim J, Michael N, Tomaras G, Haynes BF, Ferrari G. Vaccine-induced ADCC-Mediating antibodies target unique and overlapping envelope epitopes (Abstract). *AIDS VACCINE 2012, Boston, USA, Sep 9-12, 2012* p.73.

Bonsignori M, Pollara J, Moody MA, Kepler TB, Chen X, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Montefiori DC, Liao H, Ferrari G, Haynes BF. Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Preferentially Use the VH1 Gene Family (Abstract). *AIDS VACCINE 2012, Boston, USA, Sep 9-12, 2012* p.134.

Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, Devico A, Evans DT, Ferrari G, Liao HX, Haynes BF. ADCC-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. *J Virol*. 2012 Aug 15.

Htun WL, Bowonwatanuwong C, Phonrat B, Pitisuttithum P. Long Term Outcomes of Nevirapine Containing Antiretroviral Therapy at a Center in Thailand. *Southeast Asian J Trop Med Public Health*. 2012 July; 43(4):860-870.

Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, Labranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, et al. Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. *J Infect Dis*. 2012 Jun 14.

Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. *Lancet Infect Dis*. 2012 May 29; 12: 531-37.

De Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, et al. The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope. *J Immunol*. 2012 May 15;188(10):5166-5176.

Matys K, Mallary S, Bautista O, Vuocolo S, Manalastas R, Pitisuttithum P, Saah A. MATERNAL-INFANT TRANSFER OF ANTI-HPV ANTIBODIES FOLLOWING VACCINATION WITH GARDASIL(R). *Clin Vaccine Immunol*. 2012 Apr 18.

Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. *N Engl J Med*. 2012 Apr 5;366(14):1275-86.

Songthap A, Pitisuttithum P, Kaewkungwal J, Fungladda W, Bussaratid B. Knowledge, attitude, and acceptability of a human papilloma virus vaccine among students, parents and teachers in Thailand. *Southeast Asian J Trop Med Public Health*. 2012 Mar; 43(2):340-353.

Paris R, Bejrachandra S, Thongcharoen P, Nitayaphan S, Pitisuttithum P, Sambor A, Gurunathan S, Francis D, Ratto-Kim S, Karnasuta C, de Souza MS, Polonis VR, Brown AE, Kim JH, Stephens HA; for the Thai AIDS Vaccine Evaluation Group (Taveg). HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E. *Vaccine*. 2012 Jan 20;30(5):832-836.

Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W, Pungpak S, Suntharasamai P, Vanijanonta S, Nitayapan S, Kaewkungwal J, Benenson M, Morgan P, O'Connell RJ, Berenberg J, Gurunathan S, Francis DP, Paris R, Chiu J, Stablein D, Michael NL, Excler JL, Robb ML, Kim JH. Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand. *PLoS One*. 2011;6(12): e27837.

Pitisuttithum P, Rerks-Ngarm S, Chiu J, Kim J, Benenson M, Kent SJ, Tamashiro H, Manrique A, Bernstein A, Goyal R, Ditangco RA, Cooper DA, Osmanov S, Mathieson B, Sandstrom E, Esparza J, Hoff R, Shao Y for the AIDS Vaccine for Asia Network. Accelerating the development of an AIDS Vaccine: The AIDS Vaccine for Asia Network (AVAN). *Southeast Asian J Trop Med Public Health*. 2011 Sep;42(5):1130-1146.

Larsen RA, Bauer M, Pitisuttithum P, Sanchez A, Tansuphaswadikul S, Wuthiekanun V, Peacock SJ, Simpson AJ, Fothergill AW, Rinaldi MG, Bustamante B, Thomas AM, Altomstone R, Day NP, White NJ. CORRELATION

OF SUSCEPTIBILITY TESTING OF C. NEOFORMANS TO AMPHOTERICIN B WITH CLINICAL OUTCOME. Antimicrob Agents Chemother. 2011 Sep 26.

Chunpongthong P, Win Ko Ko Z, Yeekian C, Luvira V, Pitisuttithum P. Outcomes of antituberculosis treatments at 18 months follow-up in TB-HIV co-infected patients on ART: a retrospective review of 166 cases. J Med Assoc Thai 2011; 94 (6): 664-670.

Aunhachoke K, Bussaratid V, Chirachanakul P, Chua-Intra B, Dhitavat J, Jaisathaporn K, Kaewkungwal J, Kampirapap K, Khuhaprema T, Pairayayutakul K, Pitisuttithum P, Sindhvananda J, Thaipisuttikul Y; for the Thai Herpes Zoster Study Group. Measuring herpes zoster, zoster-associated pain, post-herpetic neuralgia-associated loss of quality of life, and healthcare utilization and costs in Thailand. Int J Dermatol. 2011 Apr;50(4):428-435.

Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallery S, Bautista OM, Bryan J, Vuocolo S, Haupt RM, Saah A. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011 May 31.

Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV, Self S, Turner K, Sanchez J, Pitisuttithum P, Duerr A, Dubey S, Kierstead L, Casimiro D, Hammer SM; for the Merck V520-018/HIV Vaccine Trials Network 050 Study Team. Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS Res Hum Retroviruses. 2010 Nov 23.

Kent SJ, Cooper DA, Chhi Vun M, Shao Y, Zhang L, Ganguly N, Bela B, Tamashiro H, Ditangco R, Rerks-Ngarm S, Pitisuttithum P, Van Kinh N, Bernstein A, Osmanov S; AIDS Vaccine for Asia Network investigators and supporters. AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines. PLoS Med. 2010 Sep 21;7(9):e1000331.

Pitisuttithum P, Choopanya K, Rerk-Ngam S. HIV-vaccine research and development in Thailand: evolution and challenges. Vaccine. 2010 May 26;28 Suppl 2:B45-9.

Martin M, Vanichseni S, Suntharasamai P, Mock PA, van Griensven F, Pitisuttithum P, Tappero JW, Chiamwongpaet S, Sangkum U, Kitayaporn D, Gurwith M, Choopanya K; for the Bangkok Vaccine Evaluation Group. Drug use and the risk of HIV infection amongst injection drug users participating in an HIV vaccine trial in Bangkok, 1999-2003. Int J Drug Policy. 2010 Jul;21(4):296-301

Rerks-Ngarm S, Pitisuttithum P, Ganguly N, Zhang L, Tamashiro H, Cooper DA, Vun MC, Bela B, Ditangco R, Van KN, Bernstein A, Osmanov S, Mathieson B, Kent SJ, Shao Y. Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding. Current Opinion in HIV & AIDS. 5(5):435-452, September 2010.